DOJ Drops Powell Probe; Gene Therapy Approval; Iran Tensions Rise
The Justice Department has dropped its criminal inquiry into Federal Reserve Chair Jerome Powell, clearing a path for Trump nominee Kevin Warsh's Senate confirmation. The FDA granted accelerated approval to Regeneron's Otarmeni gene therapy for deafness, which Trump showcased at the White House. Meanwhile, analysts and reporting indicate Iran is resisting diplomatic progress and leveraging control of the Strait of Hormuz amid ongoing U.S. negotiations.
Progressive outlets emphasize that the DOJ's Powell investigation was widely seen as legally unfounded and politically motivated, with prosecutors reportedly unable to identify a criminal basis, raising concerns about executive interference in independent institutions. Senator Durbin's call for an Epstein files audit reflects Democratic concerns about DOJ transparency under the Trump administration.
The factual record shows the DOJ closed its Powell investigation after prosecutors struggled to establish grounds for criminal conduct, the FDA approved a gene therapy for hereditary deafness on an accelerated pathway, and U.S.-Iran negotiations remain unresolved while Iran maintains strategic leverage over Persian Gulf shipping lanes.
Conservative outlets frame the DOJ dropping the Powell probe as clearing bureaucratic obstacles for Trump's preferred Fed leadership, and highlight the White House gene therapy event as a concrete example of deregulation and innovation producing life-changing medical results. Kevin O'Leary's criticism of a potential Spirit Airlines bailout aligns with free-market conservative principles against government intervention in failing businesses.
The factual record shows the DOJ closed its Powell investigation after prosecutors struggled to establish grounds for criminal conduct, the FDA approved a gene therapy for hereditary deafness on an accelerated pathway, and U.S.-Iran negotiations remain unresolved while Iran maintains strategic leverage over Persian Gulf shipping lanes.
The Justice Department formally ended its investigation into Fed Chair Powell, the FDA approved Regeneron's gene therapy for deafness, and Iran-U.S. negotiations show no confirmed progress as Iran leverages the Strait of Hormuz.